Académique Documents
Professionnel Documents
Culture Documents
ANTHROPOSOPHIC
PHARMACEUTICAL CODEX
APC
SECOND EDITION
11.2007
www.iaap.org.uk
Introductory Note
The IAAP is the Governing Body for National Anthroposophic Pharmacists Associations. It’s Aims and
Objectives are 1:
• To set standards for National Associations who wish to be recognised as members of the IAAP.
• To represent, at international level, anthroposophic medicine from the professional pharmacists
perspective: Anthroposophic pharmacy being seen as an “extension” of conventional pharmacy;
• To award international accreditation of Anthroposophic Pharmacists training materials and
publications;
• To facilitate colleagueship between anthroposophic pharmacists world-wide by the active building of
community between anthroposophic pharmacists;
• To act as an initiator/co-coordinator for activities which require international action.
It is in respect of this last aim that the Board is pleased to publish the 2nd edition of the Anthroposophic
Pharmaceutical Codex (APC).
The structure of this 2nd edition has substantially been revised amending the information concerning the
systematics of anthroposophic pharmacy and its substances/preparations/products. The lists of starting
materials used have been updated (nomenclature, references to official pharmacopoeias).
In order to recognise this document as an international document it is the intention of the IAAP board in
line with its international status to publish the future edition in several languages.
The APC is reviewed and updated by an anthroposophic pharmaceutical committee responsible to the
IAAP board.
Judith Klahre Parker, pharmacist, United Kingdom, Chairperson of the the British Association, BAAP,
(British Association of Anthroposophic Pharmacists), Board Member of the IAAP
Deputy: Audrey Jones, regulatory scientist, United Kingdom
Monica Mennet von Eiff, pharmacist, Switzerland, President of the Swiss association VAEPS (Verband
für Anthroposophisch Erweiterte Pharmazie in der Schweiz - Association for Anthroposophically Extended
Pharmacy in Switzerland)
Deputy: Jakob Maier, pharmacist, Switzerland, Board Member of VAEPS
Christiaan Mol, pharmacist, Germany, Chairman of the APC committee, Board Member of the IAAP,
Member of the Committee on Manufacturing Methods of the German Homoeopathic Pharmacopoeia
Peter Pedersen, pharmacist, Germany, Member of the Committee on Manufacturing Methods of the
German Homoeopathic Pharmacopoeia
Just as for the first edition of the APC the IVAA and ECPM now strongly welcome this second and
substantially amended second edition of the APC. We are thankful to the IAAP and its APC committee
because they guarantee the constant update of this important pharmaceutical work for the quality as well
as the information on anthroposophic medicinal products.
Helsinki, 15.09.2007
Brussels, 15.09.2007
Nand de Herdt
General Secretary ECHAMP
The IVAA strongly welcomes the first edition of the Anthroposophic Pharmaceutical Codex,
APC.
After more than 80 years since its beginning, anthroposophic medicine is now practised in more
than 60 countries worldwide.
Today for transparency and also educational purposes it is of paramount importance that
anthroposophic medicines are described in a pharmaceutical codex. Anthroposophic doctors
recognise that this first edition of the APC is a fundamental key work in this sense.
We therefore are grateful to the IAAP, the international umbrella organisation of professional
anthroposophic pharmacists’ associations for the publication of the first edition of the APC.
The substances used in anthroposophic medicine, the wide range of different manufacturing
methods as well as the pharmaceutical quality criteria of the preparations obtained are herewith
documented in a reliable way.
We wish that the APC will soon be recognised by any concerning authority and/or may provide
scientific material to be properly considered for the regulatory framework of all countries, where
anthroposophic medicine is practised.
We also see the chance that the APC may set quality standards for the preparation of
anthroposophic remedies by retail pharmacies.
Milan, 21.5.05
The Anthroposophic Pharmaceutical Codex (APC) contains extensive information regarding the
quality of anthroposophic medicinal products collected by the International Association of
Anthroposophic Pharmacists (IAAP). In order to provide transparency on anthroposophic
medicinal products and pharmacy, the APC describes quality standards for raw materials and
manufacturing methods. Furthermore it includes a list of substances used in anthroposophic
pharmacy.
With the intention to include relevant industry information, IAAP has consulted the ECHAMP
members concerned during the compilation of the APC.
Brussels, 01.07.2005
Nand de Herdt
General Secretary ECHAMP
L‘ECPM, fondée en 1989, est une Fédération Européenne d‘associations médicales regroupant
plus de 50.000 médecins pratiquant les Médecines Alternatives et Complémentaires (CAM)
répartis à travers tous les Etats Membres de l‘EU. Son but est de promouvoir le pluralisme des
approches médicales tant au niveau européen que dans les différents Etats Membres de l‘EU
La médecine anthroposophique existe depuis plus de 80 années et, est pratiquée dans tous les
pays européens. Les médicaments anthroposophiques sont prescrits régulièrement par un
nombre toujours grandissant de médecins membres de l‘ECPM. C‘est pourquoi nous saluons
tout particulièrement la publication de l‘Anthroposophic Pharmaceutical Codex. Nous félicitons l‘
International Association of Anthroposophic Pharmacists (IAAP), l‘organisation qui regroupe sur
un plan international les pharmaciens d‘orientation anthroposophique.
L‘APC donne des informations claires et fondamentales concernant la qualité des médicaments
anthroposophiques. L‘éventail très large des médicaments utilisés en médecine
anthroposophique et la grande diversité des modes de préparation sont très bien documentés
dans cette publication. L‘APC est donc d‘une importance capitale pour une bonne pratique de la
médecine anthroposophique mais aussi une garantie de sécurité pour les patients, à laquelle
les médecins se sentent obligés.
L‘ECPM souhaite que l‘APC soit pris en compte par les autorités de santé de tous les pays
européens car il contribue à protéger la santé publique en garantissant des médicaments de
très haute qualité.
Dr Robert KEMPENICH
Président de l‘ECPM
Foreword
Pharmacy extended by the principles of anthroposophy began to be developed at the beginning of the
20th century by Rudolf Steiner (founder of anthroposophy, 1861 - 1925) and Oskar Schmiedel (Austrian
chemist, 1887 - 1959), in collaboration with a number of physicians. Their aim was to reinterpret and
complement the results of pharmaceutical and medical research with insights gained from anthroposophic
research of the human being and nature.
The basis of anthroposophic approach to pharmacy consists in the “holistic” knowledge of mankind and
nature, which recognizes the notion that human beings and the kingdoms of nature are related through a
common evolution1.
This perception leads to a comprehensive view of substances in their relationship to health, illness and to
a specific approach to pharmacy.
Therefore anthroposophic pharmacy is using substances from the mineral, plant and animal kingdoms2,3.
Anthroposophic medicinal products have been on the market world-wide and prescribed by qualified
medical practitioners since 1921.
The range of anthroposophic medicinal products is partially determined by the physical characters of
substances, whereby allopathic, phytotherapeutic and homoeopathic criteria are taken into consideration.
Most particularly, anthroposophic medicinal products are characterised by their manufacturing processes
involving specific anthroposophic and typical homoeopathic pharmaceutical procedures. The range of
anthroposophic medicinal products includes potentised medicinal products, manufactured by using the
methods of the official homoeopathic pharmacopoeias, as well as concentrated mineral, herbal or animal
substances or preparations and compounded medicinal products. Considering this diversity,
anthroposophic medicinal products, cannot be defined under a single substance classification.
The Anthroposophic Pharmaceutical Codex APC gives an overview of substances and methods used in
the manufacture of anthroposophic medicinal products as well as of the related quality parameters.
Legal Situation
Today in the European Union Directive 2001/83/EEC gathers the main legislation concerning medicinal
products. The legal status of anthroposophic medicinal products in the EU is closely related to the that of
homoeopathic medicinal products (see below).
In fact from a regulatory point of view anthroposophic medicinal products can be devided into two
categories:
• anthroposophic medicinal products manufactured according to a homoeopathic manufacturing
method within the meaning of Directive 2001/83/EEC, article 1, 5.:
“Any medicinal product prepared from substances called homeopathic stocks in accordance with
a homeopathic manufacturing procedure described by the European Pharmacopoeia or, in
absence thereof, by the pharmacopoeias currently used officially in the Member States. (...)”
These are equally important and have never been included in any pharmacopoeia.
In many EU countries, and also world-wide, medicinal products used for the anthroposophic therapeutics
are thus partially integrated in legislation.
Anthroposophic medicinal products as a whole are thus facing the need to gain legal recognition in the
EU as well as world-wide, and among other things this requires comprehensive publication of their
pharmaceutical quality.
The relationship of the APC to Pharmacopoeia Europea, to other existing official pharmacopoeias
and non official pharmacopoeias
The APC is published by the IAAP, an independant association of professional pharmacists, within the
context of official existing pharmacopoeias.
It is the intent of the APC to refer where possible to existing pharmacopoeias.
In fact anthroposophic medicinal products are often manufactured and controlled according to existing
specifications and standards.
A part of the reference pharmacopoeias for the APC are published by official Authorities, in particular
The European Pharmacopoeia
The French Pharmacopoeia
The German Homoeopathic Pharmacopoeia (which is a part of the German Pharmacopoeia);
Furthermore
The Austrian Pharmacopoeia
The British Pharmacopoeia
The Swiss Pharmacopoiea.
In particular the European Pharmacopoeia today represents and for the future will represent a reference
of paramount importance for the APC.
Therefore in part IV of the APC containing the lists of the various substances used in anthroposophic
pharmacy reference is made where possible to the European Pharmacopoeia and other official
pharmacopoeias.
Other pharmacopoeias are referred to in the APC are not officially recognised. Nevertheless they provide
reliable standards accepted e.g. by Regulatory Authorities, in particular the British Homoeopathic
Pharmacopoeia.
The IAAP understands its task to sustain anthroposophic pharmaceutical activities at any level (e.g.
manufacturing, quality control, regulatory affairs), worldwide, that is, beyond the countries of the
European Pharmacopoeia Convention. Therefore during the evolution of the APC other official (or private
reliable pharmacopoeias) will possibly be refered to, e.g. the Brazilian Pharmacopoeia.
1 Jos Verhulst: "Der Erstgeborene“ (The first-born), publisher Verlag Freies Geistesleben, Stuttgart, D 2001.
2 Rudolf Steiner/Ita Wegman: "Grundlegendes für eine Erweiterung der Heilkunst nach geisteswissenschaftlichen
Erkenntnissen." GA 27, publisher Rudolf Steiner Verlag, Dornach, CH, 1992.
In English: "Extending Practical Medicine - Fundamental Principles based on the Science of the Spirit". Rudolf Steiner
Press, London, GB, 1996
3 Rudolf Steiner: "Geisteswissenschaft und Medizin", 20 Vorträge für Ärzte (1920), Rudolf Steiner Verlag, Dornach,
CH 1985.
In English: "Introducing Anthroposophical Medicine" (previously published as: Spiritual Science and Medicine).
Twenty lectures to doctors. Dornach 21 March - 9 April 1920, GA 312. Anthroposophic Press, Hudson, NY, USA,
1999.
Table of Content
Part I Definitions 16
1. Definition of an anthroposophic medicinal product 17
4. Active substances 26
4.1. Starting materials as active substances 26
4.2. Preparations 26
2. Metal preparations 33
6. Liquid solutions 71
7. Compositions 73
8. Potentised Preparations 79
9. Mixtures 82
Part IV Appendices 87
Appendix 2.5. Starting material that have undergone special treatment 133
Part I “Definitions” provides definitions and describes quality aspects as well as parameters related to
anthroposophic medicinal products. The different stages incurred in the obtaining of a medicinal product,
from the starting material to the dosage form, lead through this part.
In this way, the relationship between the APC and other pharmacopoeias, as well as the option to define
substances through their production methods are outlined.
General monographs
Part III, information about dosage forms in anthroposophic pharmacy as well as production methods of
specific dosage forms for anthroposophic medicinal products.
Part IV "Appendices"
In appendix I starting materials for the preparation of anthroposophic medicinal products are listed (no
excipients and vehicles). The appendices are numbered according to the related chapter in part I: 2.1.,
2.2., 2.3., 2.4., 2.5., 2.6.
In appendix II other links to the HAB as well as to the HPUS are given:
• the HAB monographs of substances used in anthroposophic pharmacy;
• the correspondence between HAB production methods used in anthroposophic pharmacy and
HPUS classes/ general pharmacy.
Glossary
In this glossary only those terms are referred to, that need extra clarification prior to the definitions given
in part I.
ANTHROPOSOPHIC
PHARMACEUTICAL CODEX
APC
PART I
Definitions
DEFINITION
An anthroposophic medicinal product is conceived, developed and produced in accordance with the
anthroposophic knowledge of man, nature, substance and pharmaceutical processing1.
An anthroposophic medicinal product can contain one or more active substances (see also Part I, chapter
4).
An anthroposophic medicinal product can fundamentally be employed in every dosage form, including
external (topical), internal and parenteral dosage forms (see also part I, chapter 5).
PRODUCTION
The active substances or dosage forms of anthroposophic medicinal products are produced:
and/or
An anthroposophic medicinal product complies with the relevant specifications/ monographs set out in
parts I and II.
RECOMMENDED DESIGNATION
Concerning the designation of anthroposophic medicinal products a reference to the APC is
recommended.
Note:
1 See IAAP brochure: "Basic Information on the Working Principles of Anthroposophic Pharmacy", 2005,
see IAAP website www.iaap.org.uk
2.6. Compositions
Starting materials for the production of anthroposophic medicinal products comply with any relevant
monograph in the European Pharmacopoeia or in the absence thereof, with the relevant monographs in
national pharmacopoeias used in the Member States, or in absence thereof with the individual
monograph.
Starting materials can be the active substances themselves or can be processed into preparations (see
also Part I, chapter 4).
Minerals are solid, crystalline components of natural origin belonging to the earth’s crust and other
celestial bodies. A mineral has a defined crystal system and crystal class. Minerals are chemically and
physically homogeneous to a significant extent. In reality, however, there are always deviations from the
theoretical mineral formula. Many minerals may show differences in their colours. Form and habitus may
be significantly different within the same type.
Rocks are composed of one or more minerals having a geological definition and distribution in their
natural deposit with a certain statistical homogeneity.
Pieces that will be used for production should be big enough to allow mineralogical identification. If a
powdered mineral is used, adequate documentation should ensure the quality and natural origin. In fact
pieces used for production must be free from visible foreign matter. They have not undergone any
unwanted mechanical or chemical treatment: in particular any chemical reaction, colouring, varnishing,
heating and artificial radiation must be excluded. The amount of foreign matter accepted after chemical
analysis is specified in the respective monograph.
Natural waters can come from a natural source (e.g. Levico), from the sea (e.g. aqua maris) or from
mineral cavities (e.g. agate water).
List of minerals, rocks, including natural waters: see part IV, appendix 2.1.
Fresh plants should be used shortly after harvest. If this is not possible, the quality is guaranteed by
appropriate measures, e.g. freezing.
If material from cultivated plants is used preference should be made for materials from plants cultivated
by biodynamic cultivation ("Demeter" certified) or by other certified organic cultivation methods in
accordance to the relevant European regulations ruling organic agricultural products (see also Council
Directive (EEC) n° 2092/91).
If wild plants are harvested protection of species according to relevant regulations is granted and special
care is taken of the eco-system concerned.
Plants or parts of plants are, as far as possible, free from impurities such as soil, dust, dirt and other
contaminants such as fungal, insect and other animal contaminations. They are not decayed.
Harvested plants or the mother tinctures made thereof are analysed for content of heavy metals and
pesticides.
The range and frequency of this testing can occur according to a monitoring plan based on risk
assessment.
Animal husbandry and keeping must be adequate for the animal species (see also Council Directive
(EEC) n° 2092/91). In particular in the case of warm-blooded species animals from well-monitored
"Demeter" or biodynamic herds are preferentially used.
The starting materials of zoological origin must meet the requirements of the European and/ or relevant
national pharmacopoeias regarding the preparation of medicinal products from materials of animal origin
and with EU directives and/or national guidelines of the appropriate regulatory authorities.
In particular the Ph. Eur. monographs on TSE safety (Ph.Eur. 50208), viral safety (Ph. Eur. 50107) apply.
Animals must be healthy and in good hygienic condition. The intervals given in legislation for the
administration of drugs to animals must be observed before the animals are used.
Health requirements, animal keeping, protection of species and processing of animals must comply with
the relevant guidelines of responsible national authorities and those of the European Union, where
applicable.
List of starting materials of zoological origin see part IV, appendix 2.3.
Starting materials that can be described chemically are inorganic and organic substances.
Organic substances are generally of natural origin, e.g. purified fractions.
Preference should be made for clearly traceable substances, that comply with the quality standards under
2.1, 2.2., 2.3.
List of starting materials that can be described chemically see part IV, appendix 2.4.
Starting materials that have undergone a special treatment are: e.g. plants, parts of plants cultivated by
special treatment (see part II, chapter 1.1. Vegetabilisation methods of substances used for mother
tinctures).
List of starting materials that have undergone special treatment see part IV appendix 2.5.
2.6. Compositions
Different starting materials described in 2.1., 2.2., 2.3., 2.4., 2.5 undergo one or more pharmaceutical
processes that will lead to a substance that cannot be described as an addition of its ingredients. The
rationale for the synthesis is an anthroposophic formula, in accordance with the anthroposophic
understanding of man and nature2.
Note:
Vehicles are auxiliary substances, which may be used for the production of active substances (e.g.
ethanol to obtain an extract or lactose monohydrate to obtain a potentised preparation). Vehicles are used
also in the production of mixtures (see part II, chapter 9).
Excipients are auxiliary substances, which may be used for the production of the pharmaceutical dosage
forms (e.g. NaCl to obtain an isotonic solution for parenteral preparations). Excipients are used also in the
production of mixtures (see part II, chapter 9).
Vehicles and excipients used in the manufacture of anthroposophic medicinal products comply with the
relevant requirements of the European Pharmacopoeia or of the national pharmacopoeias used in the EU
Member States.
4. Active substances
Starting materials used as active substances are marked with „AS“(active substance) in the starting
material lists (part IV, appendices 2.1., 2.2., 2.3., 2.4., 2.5., 2.6.).
Starting material used directly as active substances may be the final dosage form, e.g. a herbal tea.
4.2. Preparations
Preparations comply with the specifications described in part II or in the individual monograph.
Preparations can be the final dosage form or can be processed further, e.g. to obtain mixtures.
ANTHROPOSOPHIC
PHARMACEUTICAL CODEX
APC
PART II
In anthroposophic pharmacy the treatment of the raw materials can already be part of the pharmaceutical
processing, e.g. a plant can be cultivated under treatment with a metal or mineral preparation.
Metals can either be used as a concentrated starting material or undergo a pharmaceutical process
depending on the rationale of the anthroposophic therapeutics.
Preparations can be differentiated according to the thermal condition or treatment in the pharmaceutical
process. Hereby follows a scheme concerning the related pharmaceutical processes applied to plant
material and the main sphere of action.
Potentised preparations are gradually diluted substances, whereby at each diluting step a rhythmic
succussion (liquid potencies) or trituration (solid potencies) has been carried out.
During this process the surface of the vehicle and the substance to be potentised are expanded and the
mixing is thorough. The potentising time differs for solid and liquid potentised preparations. Astronomical
aspects may be considered (e.g. solar or lunar eclipse). Anthroposophic pharmacy mainly uses decimal
attenuations. For co-potentised preparations the ratio between active substances to vehicle may vary,
differing from 1:10 for homoeopathic co-potentising methods (see also part II, "Potentised Preparations").
Notes
1 General scheme for the correlation between spheres of therapeutic action/ degree of potentisation:
See also: H. M. Schramm, Heilmittel-Fibel zur anthroposophischen Medizin, 2nd edition, Novalis Verlag,
Schaffhausen, 1997, p.68
2 IAAP brochure: "Basic Information on the Working Principles of Anthroposophic Pharmacy", 2005, see
IAAP website www.iaap.org.uk
In anthroposophic pharmacy the treatment of the raw materials can already be part of the pharmaceutical
processing, e.g. a plant can be cultivated under treatment with a metal or mineral preparation.
DEFINITION
Vegetabilisation of substances is a potentising process taking place through nature. The potentising
process is carried out with plants and goes through three vegetation periods. The substance and
appropriate plant are chosen in accordance with the rationale of anthroposophic understanding of man
and nature.
Plants are treated in the first vegetation period with either a diluted metal salt or a mineral. Compost made
from this plant is used to treat plants of the second vegetation period. The plants of the second vegetation
period are used as compost to treat the third vegetation period. Mother tinctures are made from the plant
of the third vegetation period.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex
- the fertilised plant,
- the substance used,
- the designation ”cultum”, “culta”.
Example: Tabacum Cupro cultum; Equisetum arvense Silicea cultum.
For the vegetabilisation of substances of metallic origin plants are treated with a diluted metal substance.
For the vegetabilisation of Silicea plants are treated with an appropiate mineral containing silica.
2. METAL PREPARATIONS
Metals can either be used as a concentrated starting material or undergo a pharmaceutical process
depending on the rationale of the anthroposophic therapeutics.
DEFINITION
By producing metal mirrors the metal is transformed through different states of aggregation.
The metals or metal salts can be brought through a liquid state (melted or as solution), gas state or
plasmatic state to be obtained again in solid state as the pure metal.
Metal mirrors are deposits of metals in reduced state onto a surface by a specific method of production
The metal can be removed from the surface.
The following analytical tests are done always for metal used to perform the mirror. Only by the reduction
of metal salts the metal mirror obtained is tested itself as follows.
IDENTIFICATION
At least one suitable identification test is carried out.
TESTS
see the individual monograph
ASSAY
Required content according to the individual monograph.
STORAGE
Store in a well-closed container.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the metal used,
- the designation ”metallicum praeparatum” or in the case of metal mirror foil the name of the metal
followed of the word “foil”.
Example: Argentum metallicum praeparatum; Cuprum foil
Metal mirrors prepared by distillation are obtained from the pure metal.
The pure metal is heated in appropriate equipment under vacuum until it evaporates. The metal vapour
condenses onto the surface of the cooler parts of the distillation equipment, producing a metal mirror. The
metal mirror is removed from the surface.
APC Method 2.1.2. (Metal mirrors obtained by Chemical Vapour Decomposition, CVD)
Metal mirrors prepared by chemical vapour decomposition are obtained from a volatile metal compound.
A volatile metal compound is distilled under vacuum in appropriate equipment. The vapour is further
heated. Under decomposition of the metal compound, the pure metal condenses onto the surface of the
cooler parts of the distillation equipment, producing a metal mirror. The metal mirror is removed from the
surface.
Metal mirrors prepared by reduction are obtained from an appropiate metal salt.
To a solution of a metal salt an appropriate reducing agent and adjuvants are added. The pure metal
precipitates onto the surface of the reaction vessel producing the metal mirror. The metal mirror is
removed from the surface, filtered from the solution, washed with purified water and ethanol and dried.
To produce a metal mirror foil a process known as sputtering is used. In this vapour phase technique
there is no melting of the metal. The sputtering process is most commonly used for thin-film deposition of
many different metals. Ions impacting on the target can liberate sputtered neutrals.
A metal target is put under the effect of a magnetrom. A magnetrom is comprised of a cathode (electron
source) an anode (electron collector) and a combined electric and magnetic field. Vacuum conditions are
generated and an inert gas is used as medium. The process begins as a result of a collision and
momentum transfer from an incoming particle which impacts the inert gas molecules. Ions of the inert gas
impact then the surface of the metal and the result is an ejection of metal atoms from the surface. The
electric field leads to an ionisation of the metal which goes into a plasma aggregation state and
condensates as a metal mirror on the substrate, in this case a plastic foil. After this process the metal
mirror foil is stitched to a special cotton tissue directly over the metal mirror.
Tinctures and oil extracts are obtained from starting materials from botanical or zoological origin by
pharmaceutical processes under cold condition (2-8 °C), at ambient temperature (15-25 °C), with heat
treatment at different temperatures, by rhythmic application of heat and cold, by fermentation as well as
by destillation. If applicable, vehicles e.g. water, ethanol, water/ethanol mixtures, glycerol, oils may be
used.
DEFINITION
Cold treated mother tinctures are obtained from fresh (frozen) or dried vegetable matter. The maceration
is carried out at a temperature of 2-8 °C using purified water, water for injections or isotonic solution.
If necessary, the matter to be extracted is reduced to pieces of suitable size. The prescribed quantity of
extraction solvent according to the individual monograph is added to the raw material. Mix thoroughly and
allow to stand in a closed container, where applicable protected from light for an appropriate time at least
7 days. Shake or stir occasionally. Express and filter.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
pH (Ph. Eur. 2.2.3.). Where applicable, the preparation complies with the limits prescribed in the
individual monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The preparation complies with the limits prescribed in the
individual monograph.
Relative density (Ph. Eur. 2.2.5.). Where applicable, the preparation complies with the limits prescribed
in the individual monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the fresh vegetable matter used,
- where applicable, the ethanol content in the preparation,
- where applicable, the ratio of starting material to extraction liquid or of starting material to preparation.
HAB Method 38
DEFINITION
Tinctures made by maceration with water or ethanol / water are liquids and are obtained from fresh
(frozen) or dried vegetable or animal matter. The maceration is carried out at a temperature not above 25
°C by using ethanol of a suitable concentration or purified water.
If necessary, the matter to be extracted is reduced to pieces of suitable size; animals are processed
immediately after killing. The prescribed quantity of extraction solvent according to the individual
monograph is added to the raw material. Mix thoroughly and allow to stand in a closed container at the
required temperature, where applicable protected from light for an appropriate time. If necessary shake or
stir occasionally. Express and filter, if necessary.
Adjustment of the constituents. Adjustment of the content of constituents may be carried out, if necessary,
either by adding the extraction solvent of suitable concentration or by adding another macerate of the
vegetable or animal starting material used. Adjustment of content by concentration is carried out using
suitable methods, generally under reduced pressure.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Relative density (Ph. Eur. 2.2.5.). Where applicable, the macerate complies with the limits prescribed in
the individual monograph.
Ethanol content (Ph. Eur. 2.9.10.). Where applicable, the ethanol content complies with that prescribed
in the individual monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The preparation complies with the limits prescribed in the
individual monograph.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable or animal matter used,
- where applicable, the fresh vegetable or animal matter used,
- where applicable, the ethanol content in the preparation,
- where applicable, the ratio of starting material to extraction liquid or of starting material to preparation.
HAB Methods 1
Methods 2
Methods 3
Methods 4
Methods 12b, c, m, n, o
Method 49
Potentisation
Unless a different ethanol concentration is specified, use ethanol 30per cent (m/m) and then 15 per cent
(m/m) for subsequent dilutions from the D4 onwards and proceed accordingly.
Preparations according to APC Method 3.2.2. are tinctures for external use. They are prepared as follows:
maceration of dried plants or parts of plants with ethanol in a ratio of 1:10 (in analogy to Ph. Eur. 2371,
Method 4a and HAB Methods 4a or 19f or 20).
Glycerol may be added up to 10 per cent.
DEFINITION
Tinctures made by maceration with glycerol are liquids and are obtained from fresh (frozen) or dried
vegetable or animal matter. The maceration is carried out at the required temperature (not above 25 °C)
by using glycerol of a suitable concentration or a glycerol solution containing sodium chloride.
Lower animals are killed immediately before processing, the parts of warm-blooded animals are
processed immediately after killing. Killing is carried out with respect for the animal suffering.
If necessary, the matter to be extracted is reduced to pieces of suitable size. The prescribed quantity of
extraction solvent according to the individual monograph is added to the raw material. Mix thoroughly and
allow to stand in a closed container at a temperature not above 25 °C, protected from light for the
appropriate time. If necessary shake or stir occasionally. Express and filter, if necessary.
Adjustment of the constituents: Adjustment of the content of constituents may be carried out, if necessary,
either by adding the extraction solvent of suitable concentration or by adding another macerate of the
vegetable or animal starting material used. Adjustment of content by concentration is carried out using
suitable methods, generally under reduced pressure.
IDENTIFICATION
At least one chromatographic or electrophoretic (animal matter) identification test is carried out.
TESTS
Conductivity (Ph. Eur. 2.2.38.). Where applicable, the macerate complies with the limits prescribed in the
individual monograph.
Relative density (Ph. Eur. 2.2.5.). The macerate complies with the limits prescribed in the individual
monograph.
Microbiological examination (Ph. Eur. 2.6.12., 2.6.13.). Where applicable, the macerate complies with
the limits prescribed.
Microbiological quality (Ph. Eur. 5.1.4.). Category 3A or 3B respectively according to the individual
monograph.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable or animal matter used,
- where applicable, the fresh vegetable or animal matter used,
- the glycerol content of the solvent used for the preparation,
- where applicable, the ratio of starting material to extraction liquid or of starting material to macerate.
HAB Methods 41
HAB Methods 42
DEFINITION
Liquid preparations made by maceration with oil are of liquid consistency and obtained from fresh (frozen)
or dried vegetable or animal matter. The maceration is carried out at the required temperature (not above
25 °C) mostly by using arachis oil or olive oil.
If necessary, the matter to be extracted is reduced to pieces of suitable size. When animal matter is used,
lower animals are killed immediately before processing, the parts of warm-blooded animals being
processed immediately after killing. Killing is carried out with respect for the animal suffering.The
prescribed quantity of extraction solvent according to the individual monograph is added to the raw
material. Mix thoroughly and allow to stand in a closed container at the required temperature, protected
from light for the appropriate time. If necessary shake or stir occasionally. Express and filter, if necessary.
Adjustment of the constituents: Adjustment of the content of constituents may be carried out, if necessary,
either by adding the extraction solvent of suitable concentration or by adding another macerate of the
vegetable or animal starting material used.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Relative density (Ph. Eur. 2.2.5.). The oil extract complies with the limits prescribed in the individual
monograph.
Refractive index (Ph. Eur. 2.2.6.). The oil extract complies with the limits prescribed in the individual
monograph.
Peroxide value (Ph. Eur. 2.5.5.). Where applicable, the oil extract complies with the limits prescribed in
the individual monograph.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable or animal matter used,
- where applicable, the fresh vegetable or animal matter used,
- where applicable, the solvent used for the preparation,
- where applicable, the ratio of starting material to extraction liquid or of starting material to preparation.
DEFINITION
Tinctures made by percolation are of liquid consistency and prepared from fresh (frozen) or dried
vegetable matter. The percolation is carried out at room temperature using ethanol of suitable
concentration or purified water.
If necessary, reduce the matter to be extracted to pieces of suitable size. Mix thoroughly with a portion of
the prescribed extraction solvent and allow to stand for an appropriate time. Transfer to a percolator and
allow the percolate to flow slowly making sure that the matter to be extracted is always covered with the
remaining extraction solvent. The residue may be pressed out and the expressed liquid combined with the
percolate.
Adjustment of the constituents. Adjustment of the content of constituents may be carried out, if necessary,
either by adding the extraction solvent of suitable concentration or by adding another percolate of the
vegetable matter used for the preparation.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Relative density (Ph. Eur. 2.2.5.). Where applicable, the tincture complies with the limits prescribed in
the individual monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The tincture complies with the limits prescribed in the individual
monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the fresh vegetable matter used,
- where applicable, the ethanol content in the tincture,
- where applicable, the ratio of starting material to extraction liquid or of starting material to tincture.
Ph. Eur. Methods of preparation of homoeopathic stocks and potentisation (2371), Methods 4
HAB Methods 4
Prepare mother tinctures according to APC Method 3.5.1. using the percolation methods given in the Ph.
Eur. monograph "Extracts". Use 1 part of dried plant or parts of plants to 20 parts of ethanol in suitable
concentration (see HAB H.5.3), unless otherwise prescribed in the individual monograph.
If adjustment to a given concentration is necessary, calculate the amount of ethanol required to obtain the
concentration specified or used for production from equation (1) of HAB Method 1. Mix the calculated
amount of ethanol with the filtrate. Allow to stand for not less than 5 days at a temperature not exceeding
20 °C, then filter if necessary.
Potentisation
Unless a different ethanol concentration is specified, use ethanol 43 per cent (m/m) for subsequent
dilutions from the D4 onwards and proceed accordingly.
3.6. Buffered aqueous mother tinctures manufactured under exclusion of oxidative influence
DEFINITION
Buffered aqueous mother tinctures manufactured under exclusion of oxidative influence are produced by
exhaustive extraction of fresh (frozen) plants or parts of plants under the exclusion of atmospheric oxygen
with a buffer.
If the fresh plant material is not processed immediately, it must be stored in liquid nitrogen. The loss on
drying (H 2.8.1) must be determined before it is placed in liquid nitrogen.
From 1 part of the plant material 50 parts of mother tincture is generally produced. The mother tincture
corresponds to the 2nd decimal dilution (mother tincture = D2).
At first add a defined amount of ascorbate phosphate buffer solution to the plant material and then finely
reduce this mixture to a slurry. Under further size reduction, add a sufficient quantity of ascorbate
phosphate buffer solution to optimise extraction. Express, filter and adjust to the required volume with
ascorbate phosphate buffer solution.
According to the individual monograph the production of the mother tincture may require the addition of a
second extract from material of the same plant species harvested at a different season. In this case mix
the extracts in an appropriate apparatus to a composition (see Chapter 7) and then dilute in a defined
proportion with ascorbate phosphate buffer solution. This composition is the mother tincture (=D2).
Buffered aqueous mother tinctures and their liquid dilutions are exclusively intended for parenteral dosage
forms. Before they are processed to finished products, the mother tincture (D2) and the liquid dilution D3
must be stored for at least 6 weeks up to 1 year. Any eventual sediment must be excluded from the
further processing. From the 4th decimal dilution (=D4) onwards, process immediately.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Loss on drying (H 2.8.1.). Loss on drying of the residue after filtration.
Sterility (Ph. Eur. 2.6.1.). If buffered aqueous mother tinctures and their liquid dilutions are stored before
further processing, they must comply with the test "Sterility" of the European Pharmacopoeia.
Proportion of original extracts: Where applicable, the proportion of both extracts in the composition is
tested comparing two different substances in both starting extracts e.g. by HPLC.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed, airtight container.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- the amount of vegetable matter used and the amount of vegetable matter dissolved.
HAB Method 32
DEFINITION
Fermented tinctures are aqueous preparations from fresh (frozen) or dried vegetable matter obtained by
fermentation at room temperature.
If necessary, reduce the vegetable matter to pieces of suitable size. Add purified water according to the
individual monograph and mix thoroughly. If stated in the individual monograph add the prescribed
fermenting agent. Allow to stand at room temperature for the time prescribed in the individual monograph
protected from air, from light and, if necessary, from oxidation. Hereafter express.
Adjustment of the constituents. Adjustment of the content of constituents may be carried out with purified
water or add purified water to the residue and express again.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
pH (Ph. Eur. 2.2.3.). The tincture complies with the limits prescribed in the individual monograph.
Relative density (Ph. Eur. 2.2.5.). The tincture complies with the limits prescribed in the individual
monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The tincture complies with the limits prescribed in the individual
monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the dried vegetable matter used,
- where applicable, the ratio of starting material to extraction liquid or of starting material to preparation.
HAB Method 53
This procedure is followed for plants harvested in the summer and for plants of the same species,
harvested in the winter.
The mother tincture is produced by composing equal parts of the two tinctures.
Potentisation
Recommended designation
Preparations according to APC Method 3.7.1. carry the designation „ferm APC 3.7.1.“.
DEFINITION
Tinctures made by digestion are liquids prepared from fresh (frozen) or dried vegetable matter with an
additional heat treatment usually at 37 °C. The digestion is carried out by using ethanol of a suitable
concentration or purified water.
If necessary, the matter to be extracted is reduced to pieces of suitable size. The quantity of extraction
liquid is added according to the individual monograph. Mix thoroughly and warm to 37 °C. Then keep at
37 °C in a covered container. Allow to stand at this temperature for the time prescribed in the individual
monograph, stirring occasionally. After cooling, allow to stand at room temperature in a well-closed
container, protected from light for the time described in the individual monograph. Add ethanol of
appropriate percentage if prescribed. If necessary shake or stir occasionally. Express and filter, if
necessary.
Adjustment of the constituents. Adjustment of the content of constituents may be carried out by dilution,
either with the same liquid used for the digestion or with another digestion of the same raw material.
Adjustment of content by concentration is carried out carefully and generally under vacuum.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
pH (Ph. Eur. 2.2.3.). Where applicable the tincture complies with the limits prescribed in the individual
monograph.
Relative density (Ph. Eur. 2.2.5.). The tincture complies with the limits prescribed in the individual
monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The tincture complies with the limits prescribed in the individual
monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the fresh vegetable matter used,
- where applicable, the ethanol content in the tincture,
- where applicable, the ratio of starting material to extraction liquid or of starting material to tincture,
- the designation “Digestio” or "ethanol. Digestio" if ethanol is used.
HAB Methods 18
HAB Method 24b
Reduce the plants or part of plants to a suitable size unless otherwise prescribed in the monograph. The
amount of vegetable matter and purified water are defined by the monograph. Introduce the amount of
purified water into a round-bottomed flask, place in a water bath and heat up to 50 °C. Add the vegetable
matter whereby the flask should be a half to three quarters full, mix thoroughly. Close the flask
hermetically. Keep the mixture at 50 °C for 6 hours. Allow to cool to 37 °C in the course of 24 hours and
maintain this temperature for 72 hours with occasional stirring. Allow to cool. If necessary add the amount
of ethanol 94 per cent (m/m) prescribed in the monograph then express and filter.
Preparations according to APC Method 3.8.1 which are obtained without ethanol, are generally processed
immediately to solid preparations (see monograph “Solid preparations of fresh plants, plant juices and
aqueous extracts”).
DEFINITION
Tinctures made by infusion are of liquid consistency and prepared from adequately prepared dried plant
material by adding boiling purified water. If ethanol (of the prescribed concentration) is used, the
quantities of ethanol and purified water are added separately.
If necessary, the plant material is reduced to pieces of suitable size. Boiling purified water is used for
extraction. If ethanol of suitable concentration is used, the quantity of ethanol is either used prior to
extraction for moistening the dried plant material for the time prescribed or added to the mixture after
cooling. Allow to stand in a well-closed container for the time prescribed. If purified water is used as
solvent, it is also used for moistening and to make up the final mass if prescribed. Express and filter, if
necessary. If purified water is used as solvent the preparation is processed further immediately.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Relative density (Ph. Eur. 2.2.5.). The tincture complies with the limits prescribed in the individual
monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The tincture complies with the limits prescribed in the individual
monograph.
Sterility (Ph. Eur. 2.6.1.): Applicable only if the Infusion is a stored aqueous mother tincture.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light, if the tincture contains ethanol.
If aqueous tinctures made by infusion are stored they must meet the requirements of Sterility (Ph Eur.
2.6.1.).
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the ethanol content in the tincture,
- where applicable, the ratio of starting material to extraction liquid or of starting material to tincture,
- the designation “Infusum” or "ethanol. Infusum", if ethanol is used.
HAB Method 20
HAB Method 24a
Potentisation
The mother tincture is identical with the 1st decimal dilution (Ø = D1).
The 2nd decimal dilution (D2) is made from
1 part of the mother tincture and
9 parts of ethanol of the same concentration.
Use the same method to produce further decimal dilutions, progressively reducing the ethanol
concentration in the sequence 94 – 86 – 73 – 62 – 43 – 30 – 15 per cent (m/m) until the 15 per cent level
is reached.
Potentisation
The mother tincture is identical with the 1st decimal dilution (Ø = D1).
The 2nd decimal dilution (D2) is made from
1 part of the mother tincture and
9 parts of ethanol of the same concentration.
Use the same method to produce further decimal dilutions, progressively reducing the ethanol
concentration in the sequence 43 - 30 - 15% (m/m) until the 15 per cent level is reached.
Recommended designation
Preparations made according to APC Method 3.9.2. carry the designation “ethanol. stab. infusum”. The
same applies to preparations made from them.
DEFINITION
Tinctures made by decoction are of liquid consistency and prepared from fresh or dried vegetable matter
that have been allowed to boil usually with ethanol of a suitable concentration or purified water or glycerol.
If necessary, reduce the vegetable matter to pieces of suitable size, add the prescribed quantity of
extraction solvent according to the individual monograph and mix thoroughly. Heat up until boiling, if
necessary under reflux and allow to boil for the time prescribed, usually 30 min. After cooling allow to
stand in a well-closed container protected from light at room temperature for the time described in the
individual monograph. If necessary, shake or stir occasionally. Express and filter, if necessary.
Adjustment of the constituents. Adjustment of the content of constituents may be carried out by dilution,
either with the same liquid used for the decoction or with another decoction of the same raw material.
Adjustment of content by concentration is carried out carefully and generally under reduced pressure.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Relative density (Ph. Eur. 2.2.5.). The tincture complies with the limits prescribed in the individual
monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The tincture complies with the limits prescribed in the individual
monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the fresh vegetable matter used,
- where applicable, the ethanol content in the tincture,
- where applicable, the ratio of starting material to extraction liquid or of starting material to tincture,
- the designation “Decoctum” or "ethanol. Decoctum", if ethanol is used.
Potentisation
Use the same method to produce further decimal dilutions, progressively reducing the ethanol
concentration in the sequence 94 - 86 - 73 - 62 - 43 - 30 - 15 per cent (m/m) until the 15 per cent level is
reached.
DEFINITION
Oil extracts are prepared from fresh or dried vegetable matter using a fatty or mineral oil as extraction
liquid with heat.
If necessary, mince the vegetable matter to pieces of suitable size. Ethanol 94 per cent (m/m) may be
added to moisten the plant material. The prescribed quantity of the extraction liquid (mostly peanut, olive,
sesame, sunflower oil or liquid paraffin) is added and mixed thoroughly with the vegetable matter. The
mixture is heated up at the prescribed temperature and allowed to stand in a closed container for an
appropriate time. Extraction temperature and time are prescribed in the individual monograph. If
necessary, the empty space of the container is filled with a protecting gas and finally expressed and
filtered.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Relative density (Ph. Eur. 2.2.5.). The oil extract complies with the limits prescribed in the individual
monograph.
Refractive index (Ph. Eur. 2.2.6.). The oil extract complies with the limits prescribed in the individual
monograph.
Peroxide value (Ph. Eur. 2.5.5.). Where applicable, the oil extract complies with the limits prescribed in
the individual monograph.
ASSAY
An assay with quantitative limits is performed when starting materials with toxicologically relevant
substances are used.
STORAGE
Store in a well-filled, airtight container, protected from light and heat. If necessary, the empty space in the
container of oil extracts is filled with an inert gas.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the dried vegetable matter used,
- the extraction liquid used,
- where applicable, the ratio of starting material to extraction liquid or of starting material to extract,
- an indication of the extraction temperature.
Specific pharmacopoeial/APC production methods to produce oil extracts with heat treament
DEFINITION
To prepare the distillate from fresh plants or parts of plants following follow the procedure given below.
Coarsely chop and crush the plant material. Pour 8 parts of alcohol 86 per cent (m/m) over 100 parts of
plant mass. Leave to stand in a closed container for at least 24 h, then steam distil, ending the steam
distillation when 50 parts of distillate have been collected.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The preparation complies with the limits prescribed in the
individual monograph.
Relative density (Ph. Eur. 2.2.5.). Where applicable, the preparation complies with the limits prescribed
in the individual monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
Potentisation
Recommended Designation
Distillates and derived dosage forms carry the designation „destillata“.
HAB Method 52
DEFINITION
Tinctures obtained with rhythmic application of heat and cold are aqueous preparations from fresh or
dried vegetable matter or saps from fresh vegetable matter obtained by fermentation under cold and heat
application.
If necessary, the vegetable matter is minced to appropriate size. Add purified water. If stated in the
individual monograph add the prescribed fermenting agent.
It is also possible to ferment the expressed plant sap or the finely minced fresh plant without addition of
purified water.
Treat rhythmically with application of heat (generally 37 °C) and cold (generally 4 °C).
Where required, express and filter after the time prescribed in the individual monograph.
Salts, specific plant ashes, metals or minerals may be added according to the individual monograph.
IDENTIFICATION
At least one chromatographic identification test is carried out.
TESTS
pH (Ph. Eur. 2.2.3.). The preparation complies with the limits prescribed in the individual monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). The preparation complies with the limits prescribed in the
individual monograph.
Relative density (Ph. Eur. 2.2.5.). Where applicable, the preparation complies with the limits prescribed
in the individual monograph.
Methanol and 2-propanol (Ph. Eur. 2.9.11.). Maximum 0.05 per cent V/V of methanol and maximum
0.05 per cent V/V of 2-propanol, unless otherwise authorised by a national official Pharmacopoeia.
ASSAY
An assay with quantitative limits is performed when raw materials with toxicologically relevant substances
are used.
STORAGE
Store in a well-closed container, protected from light, where applicable below 15 °C.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable matter used,
- where applicable, the fresh vegetable matter used,
- where applicable, the name of the salt, metal or mineral added,
- where applicable, the ratio of starting material to extraction liquid or of starting material to preparation,
- the designation „ferm“ (with water and adjuvants) or „Rh“ (fermented plant sap without adjuvants).
HAB Method 21
HAB Method 22
HAB Methods 33
HAB Methods 34
HAB Methods 35
HAB Method 36
HAB Methods 37
HAB Methods 51
Potentisation
Aqueous dilutions
The 1st decimal dilution (D1) is made from
Prepare further dilutions in the same way, using water for injections as the vehicle at every stage.
Ethanolic dilutions
The 1st decimal dilution (D1) is made from
Prepare further dilutions in the same way, using ethanol 15 per cent (m/m) as the vehicle at every stage.
Recommended designation
Preparations made according to APC Method 3.13.1. carry the designation “Rh”; the same applies to
preparations made from them. If ethanol 15 per cent (m/m) is used from the 1st decimal dilution onwards,
state this on the label.
Potentisation
Aqueous dilutions
The 1st decimal dilution (D1) is made from
Prepare further dilutions in the same way, using water for injections as the vehicle at every stage.
Ethanolic dilutions
The 1st decimal dilution (D1) is made from
Prepare further dilutions in the same way, using ethanol 15 per cent (m/m) as the vehicle at every stage.
Recommended designation
Preparations made according to APC Method 3.13.2. carry the designation "Rh"; the same applies to
preparations made from them. If ethanol 15 per cent (m/m) is used from the 1st decimal dilution onwards,
state this on the label.
Heat treatment can be applied directly to solid staring materials from botanical or zoological origin without
addition of a vehicle. The heat treatment may be performed under presence or reduced presence of
oxygen. Solid starting materials obtained by heat include toasted preparations, carbons (Carbo) and
ashes (Cinis).
DEFINITION
Toasted preparations are obtained from dried plants or parts of plants or solid, dried animal matter by
toasting. Toasted preparations are dry, usually brownish and have an intense and characteristic odour.
The substances to be toasted are crushed, if necessary, and are strongly exposed to a heat source for
the prescribed time. During the process water evaporates and the matter becomes brown or brownish.
This is achieved through the control of the heat supply, usually 170 – 250°C and by tossing the material
during the heat supply.
Particle size of the raw material, temperature and heating time are prescribed in the individual
monograph.
IDENTIFICATION/TESTS
According to the individual monograph.
STORAGE
Store in a well-closed container.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the vegetable or animal matter used,
- the designation "tostus/a/um/".
Example: Spongia tosta
DEFINITION
Carbons are brittle, generally black substances prepared from dried vegetable or animal matter.
The plant or animal matter is heated to an approximate temperature over 200 °C under reduced presence
of oxygen to produce the carbonised deposit. The carbonised substance is powdered.
IDENTIFICATION
The identification is carried out according to the individual monograph.
TESTS
The tests are carried out according to the individual monograph,
where applicable:
- Acidity or Alkalinity,
- Acid-soluble substances,
- Adsorption power,
- Alkali-soluble coloured matter,
- Cyanide,
- Ethanol-soluble substances,
- Fluorescent substances,
- Heavy metals (Ph. Eur. 2.4.8.),
- Loss on drying (Ph. Eur. 2.2.32.),
- Sulphated ash (Ph. Eur. 2.4.14.),
- Sulphide,
- Total ash (Ph. Eur. 2.4.16.),
- Zinc.
STORAGE
Store in a well-closed container.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the name of the vegetable or animal matter used,
- the designation ”Carbo”.
Example: Carbo Gentianae
DEFINITION
Ashes are generally fine, amorphous, white, grey, beige or brown powders. They are prepared from dried
vegetable or animal matter.
The vegetable or animal matter is incinerated generally at a temperature between 500 and 700 °C.
IDENTIFICATION
The identification is carried out according to the individual monograph.
TESTS
The tests are carried out according to the individual monograph,
where applicable:
- Acid insoluble substances,
- Arsenic (Ph.Eur. 2.4.2.),
- Heavy metals (Ph.Eur. 2.4.8.),
- Loss on drying (Ph. Eur. 2.2.32.).
ASSAY
Where applicable the Cinis complies with the individual monograph.
STORAGE
Store in a well-closed container with a desiccant.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the name of the vegetable or animal substance used,
- the designation ”Cinis”.
Example: Cinis Tabaci
Solid preparations from plants are obtained either by drying fresh plants, plant juices or aqueous extracts
onto a vehicle.
DEFINITION
Solid preparations of fresh plants are obtained by drying fresh plant material onto suitable vehicles e.g.
lactose monohydrate.
The fresh plant material, which is reduced to pieces of suitable size, is mixed thoroughly with the vehicle
in order to adsorb its liquid part. The mixture is dried gently and milled if necessary.
IDENTIFICATION
At least one chromatographic test is carried out.
TESTS
Loss on drying (Ph. Eur. 2.2.32.): The solid preparation complies with the limits prescribed in the
individual monograph.
Microbiological quality (Ph. Eur. 5.1.4.): Category 3
ASSAY
An assay with quantitative limits is performed when raw materials with toxicologically relevant substances
are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the name of the plant material used,
- the quantity used,
- the vehicle used.
DEFINITION
Solid preparations of fresh plants are obtained by drying plant juices or aqueous extracts onto suitable
vehicles e.g. lactose monohydrate.
The juice expressed or the aqueous extracts from the fresh plant material is mixed thoroughly with the
vehicle. The mixture is dried gently and milled if necessary.
IDENTIFICATION
At least one chromatographic test is carried out.
TESTS
Loss on drying (Ph. Eur. 2.2.32.). The solid preparation complies with the limits prescribed in the
individual monograph.
Microbiological quality (Ph. Eur. 5.1.4.). Category 3
ASSAY
An assay with quantitative limits is performed when raw materials with toxicologically relevant substances
are used.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the name of the plant material used,
- the quantity used,
- the vehicle used.
6. LIQUID SOLUTIONS
DEFINITION
Liquid solutions are liquid preparations obtained by dissolving one or more starting materials in an
appropriate vehicle. The liquid obtained may be directly potentised.
The starting material is dissolved in the appropriate vehicle. Dissolution may require heating or stirring.
The separation of a residue may be necessary.
Where necessary, immediately after the dissolution the first potentisation step is carried out in accordance
with the individual monograph.
IDENTIFICATION
Liquid solutions are identified using a suitable method.
TESTS
Appearance (Ph. Eur. 2.2.1., 2.2.2.). Where applicable, the liquid complies with the limits described in the
individual monograph.
pH (Ph. Eur. 2.2.3.). Where applicable, the liquid solution complies with the limits prescribed in the
individual monograph.
Dry residue (Ph. Eur. 2.8.16. or H 2.2.6.). Where applicable, the liquid solution complies with the limits
prescribed in the individual monograph.
Relative density (Ph. Eur. 2.2.5.). The liquid solution complies with the limits prescribed in the individual
monograph.
ASSAY
Where applicable, liquid solutions of chemically defined starting materials are assayed.
STORAGE
Store in a well-closed container, protected from light.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the name of the substance dissolved,
- the quantity dissolved,
- where applicable, the degree of potentisation.
HAB Methods 5
7. COMPOSITIONS
Compositions are made from two or more starting materials and /or preparations with or without vehicles,
by jointly treating them with a pharmaceutical process that will lead to a new substance. The rationale for
composing is the anthroposophic understanding of man, nature, substance and processing. Compositions
may be potentised.
7.1. Compositions made by treating two or more starting materials by one or more pharmaceutical
processes.
They are obtained by combining starting materials in a defined ratio according to the individual
monograph using a specified process (e.g. specified mixing, heat treatment, a chemical process).
IDENTIFICATION/TESTS
According to the nature of the composition. The components of the composition comply with the
requirements of the relevant monographs.
RECOMMENDED LABELLING
The label states:
-the name of the composition,
-the composition of the product (quantity of the ingredients),
-reference pharmacopoeia/codex.
Examples (see appendix 2.6.): Anis-Pyrit, Ferrum-Quartz, Hepar-Magnesium, Hepar sulfuris, Kalium
aceticum comp., Plumbum mellitum, Solutio Sacchari comp. (mineral compositions according to the
model of a plant).
7.2. Compositions made by treating two or more mother tinctures with one or more mother
tinctures or dilutions by one or more pharmaceutical processes.
The concerning compositions are obtained from extracts (mother tinctures) of the same plant species
harvested at different seasons, i.e. at different stages of development.
According to the individual monograph the extracts are combined in a defined ratio by a specific
pharmaceutical process eventually using specific equipment. Adjustment of concentration by diluting, pH
adjustment, and adjustment of osmolality may be carried out.
IDENTIFICATION/TESTS
According to the nature of the composition. The components of the composition comply with the
requirements of the relevant monographs.
RECOMMENDED LABELLING
The label states:
-the name of the composition,
-the composition of the product (quantity of the ingredients),
-reference pharmacopoeia/codex.
HAB Method 32
HAB Method 38
See appendix 2.6., for example Viscum album compositions.
This procedure is followed for plants harvested in the summer and for plants of the same species,
harvested in the winter.
The mother tincture is produced by unifying equal parts of the two tinctures.
Recommended designation
Preparations according to APC Method 7.2.1. carry the designation „ferm APC 7.2.1.“.
7.3. Compositions made by treating two or more starting materials with one or more mother
tinctures which undergo one or more pharmaceutical processes together.
They are obtained by combining one or more starting materials with one or more stocks in a defined ratio
according to the individual monograph.
IDENTIFICATION/TESTS
According to the nature of the composition. The components of the composition comply with the
requirements of the relevant monographs.
RECOMMENDED LABELLING
The label states:
-the name of the composition,
-the composition of the product (quantity of the ingredients),
-reference pharmacopoeia/codex.
Examples (see appendix 2.6.): Cinis e fructibus Avenae sativae cum Magnesio phosphorico, Cissus-
Ossa.
8. POTENTISED PREPARATIONS
DEFINITION
Potentised preparations are gradually diluted substances, whereby at each diluting step a rhythmic
succussion (liquid potencies) or trituration (solid potencies) has been carried out for a defined time. The
potentising time differs for solid and liquid potentised preparations. Astronomical aspects may be
considered (e.g. solar or lunar eclipse).The preparations are defined by the number of liquid potentising or
trituration steps respectively and by the ratio between the vehicle (diluting agent) and the substance to be
potentised.
or
Liquid potencies:
The substance or mixture to be potentised is dissolved in the vehicle in the chosen ratio. Usual vehicles
for liquid potencies are water (purified or water for injections), ethanol of various concentration, glycerol,
vegetable oils. Excipients might be necessary, for example to emulsify an aqueous substance into oil.
After dissolution, rhythmic succussion is carried out. For the next potentising step one part of the first
potency and the prescribed amount of vehicle are brought together and succussed. Further potentising is
carried out in likewise manner.
STORAGE
Store in a well-closed container.
RECOMMENDED DESIGNATION
The designation states:
- the reference pharmacopoeia/codex,
- the name of the potentised substance(s),
- where applicable, the ethanol content,
- the potentising vehicle used if other than lactose monohydrate,
- the potentising ratio; decimal potencies may be designated as D or DH or X,
- the potency degree.
Example: D3 or 3 DH or 3X.
HAB Method 6
HAB Method 7
HAB Methods 8
HAB Method 12j
HAB Method 17
B.Hom.P. Method Br5
B.Hom.P. Method Br6
Co-potentised preparations are liquid dilutions potentised with a suitable vehicle. The parts of active
substances can be variable (n) and consequently the vehicle is then 10 minus n parts.
Potentisation
For the first co-potentisation stage combine and succuss 1 part of each of the n preparations with 10
minus n parts of ethanol of the appropriate concentration specified under HAB H 5.3. For each further co-
potentisation stage the ratio is 1 part of the given composed potency and 9 parts of vehicle.
Co-potentised compositions may be used to produce all types of dosage forms. Co-potentisation of
mixtures according to APC Method 8.1.1. to produce parenteral preparations or eye drops is carried out
with water for injections or an isotonic solution as diluting agent.
Recommended designation
The designation of co-potentised compositions and derived dosage forms states how many potentising
stages were carried out on the mixture as a whole adding the expressions “rhythmically diluted”.
Triturate using a machine that ensures even trituration. Suitable machines include mixers with rhythmic,
pulsating spatial inversion (e.g. "Turbula"), in combination with a sealable mixing vessel and appropriate
grinding balls as well as other machines with rotating movements such as the ball mill.
Triturate the whole amount of vehicle with the substance to be potentised.
The trituration time depends on the machine and the chosen parameters. Trituration must be between 15
and 60 minutes. It has to be ensured, that the trituration is homogeneous and that particle size reduction
is achieved.
Liquid and solid starting materials can be potentised within an ointment base.
APC-Method 8.2.1. (Ointments containing powdered solid starting materials, related to HAB
Method 48)
Ointments containing powdered solid starting materials are produced with 1 part of a powdered metal,
powdered mineral or a composition containing minerals and 9 parts of an ointment base leading to a
homogeneous ointment. This potentising step in an ointment base results in the first decimal dilution (D1).
The particle size of the powdered solid starting material must be smaller than 100 µm.
Ointments according to APC Method 8.2.1. must meet the requirements of the Ph. Eur. monograph
"Semi-solid preparations for cutaneous application".
Ointments according to APC Method 8.2.1. can be used further to produce ointments according to HAB
Method 13.
Recommended designation
Ointments according to APC Method 8.2.1. carry the desigation “APC M” and the resulting decimal
dilution “D1”.
Recommended designation
Ointments according to APC Method 8.2.2 carry the designation of the resulting degree of decimal
dilution.
9. MIXTURES
DEFINITION
Mixtures are produced from one or more active substances. Vehicles and/or excipients may be added.
Mixtures contain the sum of the active substances mixed together. A special manufacturing method is not
needed (cf.compositions). Mixtures are used to facilitate the administration of more than one active
substance in one single finished product. The mixture itself may be the final dosage form.
9.4. Mixtures of starting materials used as active substances and mother tinctures or preparations with or
without vehicles and/or excipients.
RECOMMENDED LABELLING
-the ingredients mixed and their quantity,
-reference pharmacopoeia/codex.
HAB Method 12
HAB Method 16
Dosage forms
Principally an anthroposophic medicinal product can be administered in every dosage form, including
external (topical), internal and parenteral dosage forms, with or without excipients.
A dosage form of an anthroposophic medicinal product complies with any relevant dosage form
monograph and any relevant test for that dosage form as described in the European Pharmacopoeia or in
pharmacopoeias currently used officially in the EU Member States.
Main dosage forms for anthroposophic medicinal products and concerning references to official
pharmacopoeias:
Main dosage forms for internal use Relevant pharmacopoeial specifications in:
Capsule Ph. Eur.
Dilution Ph. Eur., HAB
Globuli velati Ph. Eur., HAB
Granules Ph. Eur.
Mother tincture Ph. Eur., HAB
Oral powder, Trituration Ph. Eur., HAB
Oral drops Ph. Eur.
Pillule Ph. Eur., HAB, Ph. Fr.
Syrup Ph. Eur.
Tablet Ph. Eur., HAB
Main dosage forms for external/ topical use Relevant pharmacopoeial specifications in:
Creams Ph. Eur.
Cutaneous powder Ph. Eur.
Ear drops, solution, dilution Ph. Eur., HAB
Eye drops, solution, dilution Ph. Eur., HAB
Gel Ph. Eur., HAB
Lotion B.P.
Nasal drops, solution Ph. Eur., HAB
Nasal spray, solution Ph. Eur.
Oil HAB
Ointment Ph. Eur., HAB
Oromucosal gel, solution, spray Ph. Eur., HAB
Liquid preparations for cutaneous application Ph. Eur., HAB
Vaginalia Ph. Eur., HAB
Suppositories Ph. Eur., HAB
Main dosage forms for parenteral use Relevant pharmacopoeial specifications in:
Liquid dilution for injection Ph. Eur., HAB
Solution for injection Ph. Eur.
Dosage forms of anthroposophic medicinal products comply with pharmacopoeial standards, e.g. the
relevant monographs of the Ph.Eur. and the concerning manufacturing specifications of the HAB.
APC Pillules containing Lactose (related to HAB Method 10 and Ph. Fr.)
APC Pillules containing lactose are pillules made by applying one or more potentised liquid preparations
to saccharose pillules, which may contain up to 5 per cent of lactose. The potentising ratio usually is
1:100 (v/m or m/m). The ethanol concentration of the potentised liquid preparation(s) is at least 60 per
cent (m/m). If this is not the case and interactions are excluded, the last potentisation step for decimal
potentised preparations must be carried out with ethanol of at least 62 per cent (m/m). In case
incompatibilities are expected, use ethanol of lower concentration.
Preformed pillule sizes Ph. Eur. 3 and 6.:
Ph. Eur. size 3: 110 to 130 pillules weigh 1 g
Ph. Eur. size 6: 20 to 28 pillules weigh 1 g.
Dry the pillules after impregnation in air.
RECOMMENDED DESIGNATION
the designation states:
the amount of potentised preparation(s),
the potency degree,
the potentising ratio in case other than 1:100.
ANTHROPOSOPHIC
PHARMACEUTICAL CODEX
APC
PART IV
Appendices
(Starting materials)
Correspondence list between HAB production methods used in anthroposophic pharmacy and HPUS
classes/general pharmacy
Chmelar, J. u. Meusel, W.: Die Weiden Europas. Ziemsen-Verlag, Wittenberg Lutherstadt 1986
Erhardt, W., Götz, E., Bödeker, N. u. Seybold, S.: Zander: Handwörterbuch der Pflanzennamen. Eugen
Ulmer, Stuttgart 2000
HagerROM 2006, Hagers Handbuch der Drogen und Arzneistoffe. Springer Medizin Verlag, Heidelberg
2006
Harms, H.: Die Mistel und ihre Verbreitung in Ostwestfalen. Mitt. Dt. Dendrologischen Gesellschaft 1973
Moberg, R. u. Holmasen, I.: Flechten von Nord- und Mitteleuropa. Ein Bestimmungsbuch. Gustav Fischer,
Stuttgart 1992
Roberts, W.L., Rapp, G.R., Jr., u. Weber, J.: Encyclopaedia of Minerals. Van Nostrand, New York 1974
Rothmaler, W., Jäger, E.J. u. Werner, K. in: Rothmaler, W.: Exkursionsflora von Deutschland. Spektrum
Akademischer Verlag, Heidelberg 2000
Schindler, H. u. Helma, F.: Tiere in der Pharmazie und Medizin. Hippokrates-Verlag, Stuttgart 1961
Schmeil, O. u. Fitschen, J. : Flora von Deutschland und angrenzender Länder. Quelle & Meyer Verlag,
Heidelberg 1988
Sitte, P., Ziegler, H., Ehrendorfer, F. u. Bresinsky, A.: Strasburger: Lehrbuch der Botanik. Gustav Fischer,
Stuttgart 1991
Appendix 2.1.:
Note: Starting Materials marked with "AS" are also used as active substances.
Appendix 2.2.:
Note: Starting Materials marked with "AS" are also used as active substances.
Appendix 2.3.:
Note: Starting Materials marked with "AS" are also directly used as active substances.
Appendix 2.4.:
Note: Starting Materials marked with "AS" are also used as active substances.
Appendix 2.5.:
Note: Starting Materials marked with "AS" are also used as active substances.
Appendix 2.6.:
Compositions
Note: Substances marked with "AS" are also used as active substances.
Index
Term page(s)
abbreviations 14
acknowledgements 4, 5, 6, 7
active substance 15, 26
algae 20
anthroposophic medicinal product, definition 17
anthroposophic medicinal products 8
anthroposophic pharmaceutical associations 3
anthroposophic pharmacy 8, 28
anthroposophy 8
APC committee 2
ash process 28
ashes 65
Austrian Pharmacopoeia 9
biodynamic 20, 21
blood products 21
botanical origin, starting material of 20, 92
British Pharmacopoeia 9
buffered aqueous mother tinctures manufactured under 45
exclusion of oxidative influence
calcareous products 21
carbonisation 28
carbons 63
Chemical Vapour Decomposition 34
chemically, starting materials that can be described 22, 128
cinis 65
cold maceration 28
cold treated mother tinctures and liquid preparations 35
thereof
compositions 15, 24, 73, 136
co-potentised preparations 80
crystal class 19
decoction 28, 53
definitions 16
Demeter 20, 21
destillation 28
digestion 28, 49
Directive 2001/83/EEC 8
Directive 2029/91/EEC 20, 21
distillation 34, 57
distillation products 20
dosage forms 85
essential oils 20
ethanol/water, tinctures made by macerations with water or 37
European Pharmacopoeia 9
excipient 15, 25
fermented tinctures 47
French Pharmacopoeia 9
fungi 20
German Homoeopathic Pharmacopoeia 9
Term page(s)
glossary 15
glycerol, tinctures made by maceration with 39
Goetheanum 1
HAB 14, 143
Herbal drugs for homoeopathic preparations (2045) 9
Homoeopathic preparations (1038) 9
HPUS 14, 143
infusion 28, 51
inorganic 22
internal use, main dosage forms for 85
International Association of Anthroposophic Pharmacists, 2
IAAP
lactose monohydrate 79
legal Situation 8
lichens 20
liquid phase, treatments in 28
liquid potencies 79
liquid solutions 71
maceration 28
Medical Section 1
metabolic system 28, 29
metal 28, 31
metal mirror foil 34
metal mirrors 33, 34
metal preparations 33
Methods of preparation of homoeopathic stocks and 9
potentisation (2371)
mineral preparation 31
minerals 19, 89
Minimising the risk of transmitting animal spongiform 9
encephalopathy agents via human and veterinary medicinal
products (50208)
mixtures 82
Mother tinctures for homoeopathic preparations (2029) 9
natural waters 19, 89
nerves and senses, system of 28, 29
oil extracts with heat treatment 55
oil, liquid preparations made by maceration with 41
oleoresins 20
organic 22
organs 21
parenteral, main dosage forms for 85
percolation, tinctures made by 43
pharmaceutical process 15
pharmaceutical processes, brief description of the main 28
pharmacy extended by the principles of anthroposophy 8
pillules 86
potentisation 28
potentised preparations 79
potentising in an ointment base 81
preparation 15, 26
Term page(s)
raw material 15
raw materials, special treatments of 31
reduction 34
rhythmic application of heat and cold, tinctures obtained by 59
rhythmic processing 28
rhythmic system 28, 29
rocks 19, 89
Schmiedel, Oskar 8
solid phase, treatments in 28
solid potencies 79
solid preparations from fresh plants 67
solid preparations from plant juices or aqueous extracts 69
solid preparations from plants 67
solid starting materials obtained by heat 62
special treatment, starting materials that have undergone 23, 133
specific production methods, correlation table with general 30
monographs
starting material 15, 18, 26
Steiner, Rudolf 8
structure of the Anthroposophic Pharmaceutical Codex 13
succussion 79
Swiss Pharmacopoiea 9
symbols 14
synthesis 24
table of content 11
Tinctures (chapter in 0765) 9
tinctures and oil extracts 35
toasted preparations 62
toasting 28
topical, main dosage forms for 85
trituration 79
TSE safety (Ph.Eur. 50208) 21
vegetabilisation methods 31, 32
vegetabilised metals 32
vegetabilised silica 32
vehicle 15, 25, 79
Viral safety (50107) 9, 21
zoological origin, starting material of 21, 117